Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | MME | P08473 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234316 | 1.00 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30819465 | 1.00 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL1059519 | 0.85 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL1049889 | 0.85 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL3014643 | 0.85 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL23835494 | 0.83 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL525145 | 0.83 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL928750 | 0.83 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931219 | 0.83 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931221 | 0.83 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11913052-B2 | Cell-free protein synthesis driven metabolic engineering | NORTHWESTERN UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20200291445-A1 | CELL-FREE PROTEIN SYNTHESIS DRIVEN METABOLIC ENGINEERING | NORTHWESTERN UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| EP-1363584-A1 | TREATMENT OF DANDRUFF | UNILEVER PLC (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20020168327-A1 | Treatment of dandruff | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002067880-A1 | TREATMENT OF DANDRUFF | UNILEVER PLC (GB) | 2002-09-06 | — | — | WO | disclosed |
| US-5472698-A | Mixture of (N-acetyl)-L-serine, N-acetylcysteine and alpha-lipoic acid which promotes ceramide production in skin cells | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168327-A1 | Treatment of dandruff | CYP51A1, ERG28, SREBF1 | ACE 3751/4885KDM4E 1008/4885MAPT 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.